Executive Summary: Asia Pacific Pen Needles Market

Market Scope: Comprehensive regional analysis of the Asia Pacific pen needles sector detailing therapy types, needle configurations, safety mechanisms, purchasing modes, regulatory frameworks, and country-level profiles.
Market Valuation: Valued at USD 0.60 billion in 2025, reaching USD 0.68 billion in 2026, and projected to expand to USD 1.95 billion by 2034, growing at a robust CAGR of 14.10% from 2026 to 2034.
Primary Growth Drivers: Rising preference for pen needles over traditional syringes and vials, expanding geriatric populations, and surging diabetic patient numbers across key regional economies like China and India.

Key Market Segment Metrics

Category	Leading Segment (Base Position)	Fastest-Growing / High-Growth Segment
By Therapy	Insulin Therapy (held dominant share, driven by high chronic disease management demands)	GLP-1 Therapy (projected at high growth, fueled by rising metabolic treatments and obesity care)
By Type	Standard Needle (accounted for major share, anchored by cost-sensitivity and widespread consumer adoption)	Safety Needle (expanding rapidly, driven by institutional regulations and needle-stick injury prevention)
By Needle Length	4mm (held leading share, supported by clinical recommendations for reduced tissue trauma and pain)	6mm (fastest-growing length variant, balancing effective subcutaneous delivery across diverse patient BMI profiles)
By Mode of Purchase	Retail (dominated market share, backed by local pharmacy chains and direct consumer access)	Non-Retail (projected at high growth, propelled by home healthcare expansion and digital platforms)
By Country	Japan (market leader backed by mature healthcare infrastructure and advanced tech adoption)	India (highest CAGR growth hub driven by increasing awareness, government initiatives, and rising diabetes prevalence)

Major Market Players & Industry Landscape

Market Structure: Highly consolidated and competitive landscape featuring dominant international medical device manufacturers and regional leaders focusing on product innovation, ultra-thin needle technologies, and expanded distribution networks.

Key Companies: Becton Dickinson and Company, Novo Nordisk A/S, Terumo Corporation, Ypsomed Holding AG, and B. Braun Melsungen.

To learn more about this report,

Download Free Sample Report

Asia Pacific Pen Needles Market Size

The Asia Pacific Pen needles market size was valued at USD 0.60 billion in 2025 and is anticipated to reach USD 0.68 billion in 2026 from USD 1.95 billion by 2034, growing at a CAGR of 14.10% during the forecast period from 2026 to 2034.

Growing in the preference for pen needles rather than syringes and vials, growth in geriatric populations are the key factor that drives the APAC pen needles market. Japan accounted for the largest share of the Asia-Pacific pen needles market in 2019, whereas India is estimated to grow at the highest CAGR during the forecast period.

The Chinese pen needles market is another promising region in the Asia Pacific market. Increasing diabetic patients in this region primarily drive the growth of the market in China. China is the country with the most massive diabetic patients worldwide, with around 116 million people suffering from diabetes. Overweight people are also highly susceptible to diabetes. According to the report, obesity is assumed to account for 80-85% of the risk of developing diabetes expected to drive the market growth in this region.

Indian pen needles market is predicted to grow at the highest CAGR from 2019 to 2024. The growth of the market is attributed to increasing awareness towards the availability of the latest technological devices for diabetes care, and the Indian government is also taking initiatives to spend on diabetes care and research to improve treatment techniques and methods for diabetic patients. Rising market penetration by key players and the development of improved pen needle technologies. For instance, Terumo Japan-based company has launched advanced Nanopass 34G- the world's thinnest double tapered pen needles.

REPORT COVERAGE

REPORT METRIC	DETAILS
Market Size Available	2025 to 2034
Base Year	2025
Forecast Period	2026 to 2034
CAGR	14.10%
Segments Covered	By Therapy, Type, Needle Length, Mode Of Purchase and Region
Various Analyses Covered	Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
Countries Covered	India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, the Philippines, Indonesia, Singapore, and the Rest of APAC.
Market Leaders Profiled	Becton Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG (Switzerland), UltiMed, Inc., Allison Medical, Inc., Owen Mumford, Ltd., B. Braun Melsungen, Artsana S.p.a., HTL-STREFA S.A. and Terumo Corporation (Japan).

KEY MARKET PLAYERS

Some of the Companies that are dominating the APAC Pen Needles market include

Becton Dickinson and Company
Novo Nordisk A/S
Ypsomed Holding AG (Switzerland)
UltiMed, Inc.
Allison Medical, Inc.
Owen Mumford, Ltd.
B. Braun Melsungen
Artsana S.p.A.
HTL-STREFA S.A.
Terumo Corporation (Japan)

MARKET SEGMENTATION

This research report on the Asia Pacific Pen Needles Market has been segmented and sub-segmented into the following categories.

By Therapy

Insulin Therapy
GLP-1 Therapy
Growth Hormone Therapy

By Type

Standard Needle
Safety Needle

By Needle Length

4mm
6mm
8mm
10mm
12mm

By Mode of Purchase

Retail
Non-Retail

By Country

India
China
Japan
South Korea
Australia
New Zealand
Thailand
Malaysia
Vietnam
Philippines
Indonesia
Singapore
Rest of APAC

Trusted by 500+ companies. We respect your privacy and never share your data.

Please wait. . . . Your request is being processed

Asia Pacific Pen Needles Market Report